1. Search Result
Search Result
Results for "

potentiator

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Peptides

3

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3985

    Bradykinin potentiating peptide B

    Angiotensin-converting Enzyme (ACE) Others
    Bradykinin potentiator B (Bradykinin potentiating peptide B) is venom of Agkistrodon halys blomhoffi. Bradykinin potentiator B is a potent ACE inhibitor. Bradykinin potentiator inhibits the activity of bradykinin inhibitory peptidase .
    Bradykinin potentiator B
  • HY-108450

    Poligodial; Tadeonal

    Fungal Infection Inflammation/Immunology
    Polygodial (Poligodial) is an antifungal potentiator . Polygodial is a sesquiterpene with anti-hyperalgesic properties .
    Polygodial
  • HY-15442

    BINA

    mGluR Neurological Disease
    Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders .
    Biphenylindanone A
  • HY-113319

    Endogenous Metabolite Cancer
    β-D-Fructose is a β-fruit sugar that can be produced by the hydrolysis of sucrose. β-D-Fructose can be used as a sweetness potentiator. β-D-Fructose can be designed as a units of antiproliferative agents against breast (MCF-7) and colon (MDST8) cancer cell lines .
    β-D-Fructose
  • HY-161753

    CFTR Inflammation/Immunology
    CFTR potentiator 1 (I1421) is a potent CFTR potentiator with an EC50 value of 64 nM. CFTR potentiator 1 allosterically activates a wide range of CF-causing mutants, such as ΔF508 and G551D CFTR .
    CFTR potentiator 1
  • HY-147352

    iGluR Neurological Disease
    NMDA receptor potentiator-1 (Compound 1368) is a subunit selective NMDA receptor potentiator with IC50s of 4 μM and 5 μM against NR2C and NR2D expression, respectively .
    NMDA receptor potentiator-1
  • HY-P3991

    Angiotensin-converting Enzyme (ACE) Metabolic Disease
    Bradykinin potentiator C is a potent angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 7.1 μM for rabbit lung ACE. Bradykinin potentiator C is a postulated prototype of functional peptide .
    Bradykinin potentiator C
  • HY-120811

    iGluR Neurological Disease
    PF-04701475 is a potent AMPA receptor potentiator with an EC50 of 123 nM. PF-04701475 can be used for the study of neurological disorders .
    PF-04701475
  • HY-161839

    Aldose Reductase Cancer
    AKR1C2/3-IN-1 (compound 3a) is a potent AKR1C2 and AKR1C3 inhibitor with IC50 values of 90, 50 nM, respectively. AKR1C2/3-IN-1 can be used as a radiation sensitizer and as a potentiator of chemotherapy cytotoxicity .
    AKR1C2/3-IN-1
  • HY-117517

    Others Cancer
    NG-012, potentiator of nerve growth factor (NGF), were isolated from the culture broth of Penicillium verruculosum F-4542. NG-012 potentiates the neurite outgrowth induced by NGF in rat pheochromocytoma cell line (PC12) .
    NG-012
  • HY-149861

    Others Infection
    Mip-IN-1(S,S-28i)is a new rapamycin-derived macrophage infectivity potentiator (Mip) inhibitor. Mip-IN-1 displays strong anti-enzymatic activity against the Mip proteins of Neisseria meningitidis and Neisseria gonorrhoeae and substantially improved the ability of macrophages to kill the bacteria .
    Mip-IN-1
  • HY-P1649B
    SPR741 acetate
    3 Publications Verification

    NAB741 acetate

    Bacterial Antibiotic Infection
    SPR741 acetate (NAB741 acetate) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 acetate increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 acetate inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 acetate .
    SPR741 acetate
  • HY-P1649

    NAB741

    Bacterial Antibiotic Infection
    SPR741 (NAB741) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 .
    SPR741
  • HY-P1649A

    NAB741 TFA

    Bacterial Antibiotic Infection
    SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 TFA increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 TFA inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 TFA .
    SPR741 TFA
  • HY-103369

    CFTR Endocrinology
    PG01 is a potent CFTR Cl - channel potentiator. PG01 can correct gating defects of CFTR mutants, is effective on b>E193K, G970R and G551D (CFTR mutants) with Kd values of 0.22 μM, 0.45 μM and 1.94 μM, respectively. PG01 is also effective on ΔF508 (Ka of 0.3 μM). PG01 increases ΔF508-CFTR Cl - current after adding Forskolin .
    PG01
  • HY-10934

    LY451395

    iGluR Neurological Disease
    Mibampator (LY451395) is a potent and highly selective potentiator of the AMPA receptors.
    Mibampator
  • HY-13017A

    VX-770 benzenesulfonate

    CFTR Autophagy Endocrinology
    Ivacaftor benzenesulfonate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.
    Ivacaftor benzenesulfonate
  • HY-B1056

    Propazol; 2-Benzimidazolepropionic acid

    Bacterial Infection
    Procodazole is a non-specific active immunoprotective agent against viral and bacterial infections, used as a potentiator.
    Procodazole
  • HY-13017B

    VX-770 hydrate

    CFTR Autophagy Endocrinology
    Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.
    Ivacaftor hydrate
  • HY-139715

    NF-κB Cancer
    IMD-ferulic is a covalently linked NF-κB modulator that improves the adjuvanticity of small molecule immune potentiators.
    IMD-ferulic
  • HY-18699
    CIQ
    1 Publications Verification

    iGluR Neurological Disease
    CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
    CIQ
  • HY-139717

    NF-κB Cancer
    IMD-biphenylA is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves the adjuvanticity of small molecule immune potentiators.
    IMD-biphenylA
  • HY-10935
    LY450108
    1 Publications Verification

    iGluR Neurological Disease
    LY450108 is a potent AMPA receptor potentiator. LY450108 has the potential for depression and Parkinson's disease research .
    LY450108
  • HY-112781

    PF-04958242

    iGluR Neurological Disease
    Pesampator (PF-04958242) is a potent and highly selective positive allosteric modulator of AMPA receptor (an AMPA potentiator) with an EC50 of 310 nM and a Ki of 170 nM .
    Pesampator
  • HY-123371

    Others Cancer
    Ro 07-1902 is an effective antitumor potentiator that can significantly enhance the antitumor effect of CCNU against KHT sarcoma at low doses .
    Ro 07-1902
  • HY-111099

    ABBV-974

    CFTR Autophagy Others
    GLPG1837 is a potent and reversible CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively.
    GLPG1837
  • HY-145126

    CFTR Others
    CP-628006, a small molecule CFTR potentiator, restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    CP-628006
  • HY-147367

    Others Neurological Disease
    AM-1488 is a potent, orally active glycine receptor (GlyR) potentiator (hGlyRα3 EC50=0.45 μM) .
    AM-1488
  • HY-119936

    CFTR Autophagy Inflammation/Immunology
    GLPG2451 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, which effectively potentiates low temperature rescued F508del CFTR with an EC50 of 11.1 nM .
    GLPG2451
  • HY-136939

    CFTR Metabolic Disease Inflammation/Immunology
    CFTR corrector 6 is a potent potentiator of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). CFTR corrector 6 has the potential for cystic fibrosis (CF) and other CFTR associated disorders research .
    CFTR corrector 6
  • HY-107683

    nAChR Neurological Disease
    LY-2087101 is an allosteric potentiator of α7 nAChRs. LY-2087101 causes potentiation of agonist-evoked α7 responses by binding within the nAChR transmembrane region .
    LY-2087101
  • HY-134598A

    Epigenetic Reader Domain Cancer
    653-47 hydrochloride, a potentiator, significantly potentiates the cAMP-response element binding protein (CREB) inhibitory activity of 666-15. 653-47 hydrochloride is also a very weak CREB inhibitor with IC50 of 26.3 μM .
    653-47 hydrochloride
  • HY-134598

    Epigenetic Reader Domain Cancer
    653-47, a potentiator, significantly potentiates the cAMP-response element binding protein (CREB) inhibitory activity of 666-15. 653-47 is also a very weak CREB inhibitor with IC50 of 26.3 μM .
    653-47
  • HY-13017
    Ivacaftor
    5 Publications Verification

    VX-770

    CFTR Autophagy Endocrinology
    Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively.
    Ivacaftor
  • HY-143891

    TGF-β Receptor Others
    Chromenone 1 is a potent osteogenic bone morphogenetic protein (BMP) potentiator. Chromenone 1 exhibits a unique mode of action as it induces a pronounced, kinase-independent, negative TGFβ feedback that enhances nuclear BMP-Smad signaling outputs .
    Chromenone 1
  • HY-139718

    NF-κB Inflammation/Immunology
    IMD-biphenylB is a potent imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
    IMD-biphenylB
  • HY-109177

    QBW251

    CFTR Inflammation/Immunology
    Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research .
    Icenticaftor
  • HY-116152S

    Ciprofol-d6; HSK3486-d6

    Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Cipepofol-d6 (Ciprofol-d6; HSK3486-d6) is deuterium labeled Cipepofol (HY-116152). Cipepofol (HSK3486), a psychomotor stabilizing agent, is a gamma-aminobutyric acid (GABA) receptor potentiator.
    Cipepofol-d6
  • HY-116152S2

    Ciprofol-d6-2; HSK3486-d6-2

    Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Cipepofol-d6-2 (Ciprofol-d6-2; HSK3486-d6-2) is deuterium labeled Cipepofol (HY-116152). Cipepofol (HSK3486), a psychomotor stabilizing agent, is a gamma-aminobutyric acid (GABA) receptor potentiator.
    Cipepofol-d6-2
  • HY-107508

    mGluR Neurological Disease
    VU-29 is a positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor (EC50=9 nM and Ki=244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC50: rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM) .
    VU-29
  • HY-14563

    mAChR Neurological Disease
    VU10010 is a potent, highly selective and allosteric M4 mAChR potentiator with an EC50 of 400 nM. VU10010 binds to an allosteric site on M4 mAChR and increases affinity for acetylcholine and coupling to G proteins. VU10010 increases carbachol-induced depression of transmission at excitatory but not inhibitory synapses in the hippocampus .
    VU10010
  • HY-107701

    iGluR Neurological Disease
    CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 hydrochloride acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity .
    CGP 78608 hydrochloride
  • HY-13017S2

    VX-770-d18

    Autophagy CFTR Endocrinology
    Ivacaftor-d18 is the deuterium labeled Ivacaftor[1]. Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively[2].
    Ivacaftor-d18
  • HY-107701A

    iGluR Neurological Disease
    CGP 78608 is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). CGP 78608 has anticonvulsant activities .
    CGP-78608
  • HY-150650

    Others Cancer
    S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer agent resistance .
    S07-2001
  • HY-13017S3

    VX-770-d4

    CFTR Endocrinology
    Ivacaftor-d4 (VX-770-d4) is the deuterium labeled-Ivacaftor (HY-13017). Ivacaftor is a potent and orally active CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively .
    Ivacaftor-d4
  • HY-16654

    mGluR Neurological Disease
    ML254 is a potent mGlu5 potentiator, with EC50 and pEC50 of 9.3 nM and 8.03 nM for rat mGlu5, respectively. ML254 can be used for researching schizophrenia . ML254 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ML254
  • HY-120523

    iGluR Neurological Disease
    UBP646 is a potent GluN1/GluN2D receptors potentiator, and also potentiates the other three subtypes, GluN1/GluN2A, GluN1/GluN2B, and GluN1/GluN2C receptors .
    UBP646
  • HY-150649

    Others Cancer
    S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer agent resistance .
    S07-2005 (racemic)
  • HY-115553

    Dopamine Receptor Neurological Disease
    DETQ is a selective, allosteric and orally active dopamine D1 receptor (Dopamine Receptor) potentiator. In HEK293 cells expressing the human D1 receptor, DETQ increases cAMP with an EC50 of 5.8 nM and a Kb of 26 nM. DETQ shows ~30-fold less potent at rat and mouse D1 receptors and is inactive at the human D5 receptor .
    DETQ

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: